Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions. Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth.
From Entero Healthcare Solutions Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions.
- Organic growth is expected to contribute significantly, with pharma and MedTech segments both equally driving growth.
- The company anticipates gross margin expansion, driven by scale and playing a full commercial role in certain product lines.
- They expect calendarization impacts of around 11% in revenue growth.
- Outperformance versus industry growth is targeted at around 1.4x to 1.5x the Indian Pharmaceutical Market (IPM) growth rate.
- The focus will be on profitable revenue growth, operational efficiencies, and higher-margin businesses while rationalizing low-margin segments.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Entero Healthcare Solutions Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No explicit mention of new acquisitions planned for FY '27; focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones.
- Company aims to spend more time organically building and optimizing the business platform rather than chasing new acquisition targets.
- Investment in working capital is largely in place as of Q4 FY26; incremental working capital needs will not be significant unless growth exceeds the guided 23%.
- Depreciation increase is driven by MedTech segment, notably in IVD (In Vitro Diagnostics) equipment placed at customer sites under reagent rental models.
2 more points management made on capital expenditure plans
Top-ranked in Retailing
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Entero Healthcare Solutions Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Entero Healthcare Solutions Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.9K Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Entero Healthcar's management said in earlier quarters
Others in Retailing this season
- Bhatia Communications & Retail (India) Ltd (Q4 FY26)
171.94 crores, up 65% YoY from Rs. Key concall takeaways from Bhatia Communications & Retail (India) Ltd's Q4 FY26 earnings call — and how it ranks against…
- Baazar Style (Q4 FY26)
Q4FY26 Revenue From Operations: Rs 4,657 Mn, up 35% YoY from Rs 3,452 Mn in Q4FY25 (Pages 6, 7, 15, 16). Key concall takeaways from Baazar Style Retail Ltd's…
- Just Dial Ltd (Q4 FY26)
Operating Revenue (4Q FY26):** ₹3,072 million, up 6.2% YoY from ₹2,892 million in 4Q FY25 (Page 55). Key concall takeaways from Just Dial Ltd's Q4 FY26…
- TCC Concept Ltd (Q4 FY26)
Q4 FY26 Revenue from Operations:** ₹839.0 Mn, +160% YoY (Page 34) . Key concall takeaways from TCC Concept Ltd's Q4 FY26 earnings call — and how it ranks…
Frequently Asked Questions
What were Entero Healthcare Solutions Ltd Q4 FY26 results?
Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions. Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth.
What is Entero Healthcare Solutions Ltd share price analysis?
Entero Healthcare Solutions Ltd currently shows a neutral. The stock trades at a P/E of 46.3 with a market cap of ₹5,479 Cr. Investors should review the full earnings analysis for detailed insights.
Is Entero Healthcare Solutions Ltd planning capital expenditure?
No explicit mention of new acquisitions planned for FY '27; focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones.
Keep Entero Healthcare Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.